Amneal Pharmaceuticals Q2 Adjusted EPS $0.19 Beats $0.10 Estimate, Sales $599.05M Beat $562.49M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amneal Pharmaceuticals reported Q2 earnings of $0.19 per share, beating the analyst consensus estimate of $0.10 by 90%. The company also reported quarterly sales of $599.05 million, surpassing the analyst consensus estimate of $562.49 million by 6.50%. This represents a 7.10% increase over sales from the same period last year.
August 04, 2023 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amneal Pharmaceuticals exceeded Q2 earnings and sales estimates, which could positively impact its stock price.
Amneal Pharmaceuticals reported higher than expected earnings and sales for Q2. This outperformance is typically viewed positively by investors and could lead to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100